Vineet Laboratories Limited

VINEETLAB

INE505Y01010

Pharmaceuticals

Delayed NSE India S.E. Other stock markets 05:01:06 2026-01-22 am EST			5-day change	1st Jan Change
33.05 ^INR	-1.67%		-0.36%	-10.14%

Dec. 17	Vineet Laboratories says rights issue price set at 30 rupees per share	RE
Nov. 27	Vineet Laboratories Gets Board Nod to Raise Up to INR300 Million via Rights Issue	MT

Vineet Laboratories Gets Board Nod to Raise Up to INR300 Million via Rights Issue

Published on 11/27/2025 at 03:08 am EST

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Vineet Laboratories Limited

Dec. 17	Vineet Laboratories says rights issue price set at 30 rupees per share	RE
Nov. 27	Vineet Laboratories Gets Board Nod to Raise Up to INR300 Million via Rights Issue	MT
Nov. 27	Vineet Laboratories to raise funds up to 300 million rupees via rights issue	RE
Nov. 24	Vineet Laboratories to consider rights issue	RE
Nov. 08	Vineet Laboratories Limited Announces Resignation of Hari Priya Yerukalapudi as Independent Director, Effective November 08, 2025	CI
25-09-16	Vineet Laboratories Limited Approves the Appointment of Premananda Reddy Vennapusa as Non-Executive Director, Effective from September 15, 2025	CI
25-07-22	Vineet Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2025	CI
25-05-12	Vineet Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2025	CI
24-11-13	Vineet Laboratories Limited Announces Resignation of Bhaskara Reddy Karna as Independent Director	CI
24-11-13	Vineet Laboratories Limited Reports Earnings Results for the Half Year Ended September 30, 2024	CI
24-08-13	Vineet Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2024	CI
24-05-29	Vineet Laboratories CEO Resigns	MT
24-05-29	Vineet Laboratories Limited Announces Resignation of Satish Pandurang Samant as Executive Director	CI
24-05-29	Vineet Laboratories Limited Announces Resignation of Satish Pandurang Samant as Chief Executive Officer	CI
24-05-29	Vineet Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	CI
24-02-12	Vineet Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	CI
23-11-10	Vineet Laboratories Limited Announces Appointment of Mr. Rameshkumar Bandari as Company Secretary and Compliance Officer	CI
23-11-10	Vineet Laboratories Limited Reports Earnings Results for the Half Year Ended September 30, 2023	CI
23-10-28	Vineet Laboratories Limited Announces Resignation of Nirosha Ravikanti as Company Secretary / Compliance Officer of the Company	CI
23-10-16	Vineet Laboratories Names CEO	MT
23-10-16	Vineet Laboratories Limited Appoints Mr. Satish Pandurang Samant as Chief Executive Officer	CI
23-10-16	Vineet Laboratories Limited Appoints Mr. Satish Pandurang Samant as an Additional Executive Director	CI
23-09-30	Vineet Laboratories Limited Appoints Ranga Raju Alluri as Non-Executive Director	CI
23-08-12	Vineet Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	CI
23-08-12	Vineet Laboratories Limited Announces Board Changes	CI

Chart Vineet Laboratories Limited

Duration

Period

VINEETLAB: Dynamic Chart

Vineet Laboratories Limited is an India-based company engaged in the business of drug intermediates and bulk drugs. The Company specializes in pharmaceutical intermediates and fine chemicals. Its active pharmaceutical ingredient (API) intermediates products include Lopinavir, Ritonavir, Efavirenz, Nadolol, Glimepiride, Celecoxib, and Piroctone Olanine. Its fine chemicals and reagents include Isopropyl-beta-D-thiogalactopyranoside, 4-Nitrophenyl phosphate disodium salt, 5-Bromo-4-chloro-3-indolyl-beta-D-galactopyranoside (X-Gal), 5-Acetyl thiophene-2-carboxilic acid, n-Butyl Lithium, n-Butyl magnesium chloride, 3-Furaldehyde, 3-bromofuran, 1-methyl-imidazole-2-carboxaldehyde, 6-Aminouracil, Ethyldiazo acetate, and Phenylboronic acid. The Company also exports API intermediates, fine chemicals, and custom synthesis molecules.

Employees

Sector

Pharmaceuticals

Calendar

Feb. 07 - Extraordinary Shareholders Meeting

More about the company